Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $39.86 Average Target Price from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has been assigned an average rating of “Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $39.86.

A number of equities research analysts recently issued reports on the stock. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 19th.

Oruka Therapeutics Price Performance

ORKA stock opened at $11.02 on Friday. The company has a market capitalization of $385.70 million, a P/E ratio of -1.76 and a beta of 0.77. The business has a 50 day simple moving average of $15.62. Oruka Therapeutics has a 12 month low of $10.61 and a 12 month high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $1,037,000. Wellington Management Group LLP bought a new stake in shares of Oruka Therapeutics in the third quarter valued at about $2,013,000. Franklin Resources Inc. bought a new stake in shares of Oruka Therapeutics in the third quarter valued at about $17,661,000. Point72 Asset Management L.P. acquired a new stake in Oruka Therapeutics during the third quarter worth about $11,822,000. Finally, Geode Capital Management LLC bought a new position in Oruka Therapeutics during the third quarter valued at about $343,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.